Oncology disease model cell lines
Sigma Life Science
Sigma Life Science, the biological products and services research business of Sigma-Aldrich, announces the addition of new genetically modified cancer cells to the company's range of high-quality cell lines. Sigma's CompoZr Oncology Disease Model cell lines are designed to enable basic research and high- content, high-throughput screening of compounds and biologics. Sigma will start its offering with cell lines that model colorectal and lung cancer. Later this year, this portfolio will expand with the introduction of a panel of genetically modified cell lines that model breast cancer.